1
Kenneth D Wild Jr, James J S Treanor, Haichun Huang, Heather Inoue, Tie J Zhang, Frank Martin: Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors. Amgen, Medarex, McDonnell Boehnen Hulbert & Berghoff, October 13, 2009: US07601818 (22 worldwide citation)

This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related ...


2
Kenneth D Wild Jr, James J S Treanor, Haichun Huang, Heather Inoue, Tie J Zhang, Frank Martin: Nucleic acids encoding human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors. Amgen, McDonnell Boehen Hulbert & Berghoff, September 14, 2010: US07795413 (18 worldwide citation)

This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related ...


3
Kenneth D Wild Jr, James J S Treanor, Haichun Huang, Heather Inoue, Tie J Zhang, Frank Martin: Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors. Amgen, McDonnell Boehnen Hulbert & Berghoff, January 31, 2012: US08106167 (10 worldwide citation)

This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of these antibodies and methods for neutralizing NGF function, and particularly for treating NGF-relate ...


4
Kenneth D Wild Jr, James J S Treanor, Haichun Huang, Heather Inoue, Tie J Zhang, Frank Martin: Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors. Amgen, McDonnell Boehnen Hulbert & Berghoff, June 12, 2012: US08198410 (8 worldwide citation)

This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related ...


5
Kenneth D Wild Jr, James J S Treanor, Haichun Huang, Heather Inoue, Tie J Zhang, Frank Martin: Methods of treating conditions caused by increased expression of nerve growth factor (NGF) or increased sensitivity to NGF using anti-NGF neutralizing antibodies as selective NGF pathway inhibitors. Amgen, E R Squibb & Sons L L C, McDonnell Boehnen Hulbert & Berghoff, February 16, 2016: US09260514

This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of these antibodies and methods for neutralizing NGF function, and particularly for treating NGF-relate ...


6
Kenneth D Wild JR, James JS Treanor, Haichun Huang, Heather Inoue, Tie J Zhang, Frank Martin: Human Anti-NGF Neutralizing Antibodies as Selective NGF Pathway Inhibitors. Amgen, Medarex, April 21, 2011: US20110091476-A1

This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related ...


7
Kenneth D Wild JR, James JS Treanor, Haichun Huang, Heather Inoue, Tie J Zhang, Frank Martin: Human Anti-NGF Neutralizing Antibodies as Selective NGF Pathway Inhibitors. Amgen, Medarex, Mcdonnell Boehnen Hulbert & Berghoff, February 17, 2011: US20110040076-A1

This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related ...


8
Kenneth D Wild JR, James JS Treanor, Haichun Huang, Heather Inoue, Tie J Zhang, Frank Martin: Human Anti-NGF Neutralizing Antibodies as Selective NGF Pathway Inhibitors. Amgen, Medarex, Mcdonnell Boehnen Hulbert & Berghoff, February 11, 2010: US20100034818-A1

This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related ...


9
Kenneth D Wild JR, James JS Treanor, Haichun Huang, Heather Inoue, Tie J Zhang, Frank Martin: Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors. Amgen, Medarex, Mcdonnell Boehnen Hulbert & Berghoff, June 18, 2009: US20090155274-A1

This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related ...


10